search
Back to results

CPL-01 in the Management of Postoperative Pain After Bunionectomy

Primary Purpose

Bunion

Status
Recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Local anesthetic injection of CPL-01
Naropin, 0.5% Injectable Solution
Placebo
Sponsored by
Cali Pharmaceuticals LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bunion

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Ability to sign ICF Bunion for elective primary unilateral, distal, first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia, without collateral procedures or additional surgeries BMI ≤ 39 kg/m2 If biologically female, not pregnant or planning to become pregnant over the study If biologically male, either sterile or using acceptable form of birth control Be willing and able to complete study procedures Exclusion Criteria: Has previously undergone unilateral simple bunionectomy. Has a planned concurrent surgical procedure Has a concurrent painful condition that may require analgesic treatment during the study period or may confound postsurgical pain assessments Has a history or clinical manifestation of significant medical, neuropsychiatric, or other condition that could preclude or impair study participation or interfere with study assessments. Has a history of malignant hyperthermia or glucose-6-phosphate dehydrogenase deficiency. Has history or evidence of impaired liver function (e.g., alanine aminotransferase [ALT] > 3 × upper limit of normal [ULN] or total bilirubin > 2 × ULN), active hepatic disease, or cirrhosis. Has history or evidence of impaired renal function (e.g., creatinine > 1.5 × ULN). Has a history of malignancy in the past year Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months

Sites / Locations

  • Todd BertochRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Placebo Comparator

Arm Label

CPL-01

Ropivacaine HCl

Placebo

Arm Description

Local infiltration of study drug

Local infiltration of study drug

Local infiltration of study drug

Outcomes

Primary Outcome Measures

Cumulative Pain Score
Area Under the Curve of the Numeric Rating Scale Score for Pain with Activity. Activity is resting the operative foot with the ball on the floor. Pain Score spans from 0 to 10, where 0 is no pain and 10 is worst pain imaginable.

Secondary Outcome Measures

Full Information

First Posted
April 3, 2023
Last Updated
August 28, 2023
Sponsor
Cali Pharmaceuticals LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05831449
Brief Title
CPL-01 in the Management of Postoperative Pain After Bunionectomy
Official Title
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of CPL-01 in the Management of Postoperative Pain After Unilateral Distal First Metatarsal Bunionectomy With Osteotomy
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 22, 2023 (Actual)
Primary Completion Date
March 31, 2024 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cali Pharmaceuticals LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Subjects receive study drug during bunionectomy and are followed for pain and opioid use, with the hypothesis that those who receive CPL-01 will have less pain and less opioid use than either control arm.
Detailed Description
After signing informed consent, subjects will be randomly assigned to receive study drug (either Investigational product, positive control, or negative control) during unilateral distal bunionectomy with osteotomy. Subjects will then remain at the hospital for 72-hours where pain and rescue medication usage will be assessed. Follow-up will then occur at 7 and 30 days afterwards. The hypothesis is that subjects who receive CPL-01 will have less pain and require fewer opioids than subjects in the other two arms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bunion

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
574 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CPL-01
Arm Type
Experimental
Arm Description
Local infiltration of study drug
Arm Title
Ropivacaine HCl
Arm Type
Active Comparator
Arm Description
Local infiltration of study drug
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Local infiltration of study drug
Intervention Type
Drug
Intervention Name(s)
Local anesthetic injection of CPL-01
Other Intervention Name(s)
CPL-01, Long-acting ropivacaine
Intervention Description
Local anesthetic injection (either IP, positive control [Naropin], or negative control [saline placebo])
Intervention Type
Drug
Intervention Name(s)
Naropin, 0.5% Injectable Solution
Other Intervention Name(s)
ropivacaine HCl
Intervention Description
Local anesthetic injection (either IP, positive control [Naropin], or negative control [saline placebo])
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Saline placebo
Intervention Description
Local anesthetic injection (either IP, positive control [Naropin], or negative control [saline placebo])
Primary Outcome Measure Information:
Title
Cumulative Pain Score
Description
Area Under the Curve of the Numeric Rating Scale Score for Pain with Activity. Activity is resting the operative foot with the ball on the floor. Pain Score spans from 0 to 10, where 0 is no pain and 10 is worst pain imaginable.
Time Frame
72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ability to sign ICF Bunion for elective primary unilateral, distal, first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia, without collateral procedures or additional surgeries BMI ≤ 39 kg/m2 If biologically female, not pregnant or planning to become pregnant over the study If biologically male, either sterile or using acceptable form of birth control Be willing and able to complete study procedures Exclusion Criteria: Has previously undergone unilateral simple bunionectomy. Has a planned concurrent surgical procedure Has a concurrent painful condition that may require analgesic treatment during the study period or may confound postsurgical pain assessments Has a history or clinical manifestation of significant medical, neuropsychiatric, or other condition that could preclude or impair study participation or interfere with study assessments. Has a history of malignant hyperthermia or glucose-6-phosphate dehydrogenase deficiency. Has history or evidence of impaired liver function (e.g., alanine aminotransferase [ALT] > 3 × upper limit of normal [ULN] or total bilirubin > 2 × ULN), active hepatic disease, or cirrhosis. Has history or evidence of impaired renal function (e.g., creatinine > 1.5 × ULN). Has a history of malignancy in the past year Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Erol Onel
Phone
2038376500
Email
e.onel@calibiosciences.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Erol Onel
Organizational Affiliation
Cali Biosciences
Official's Role
Study Director
Facility Information:
Facility Name
Todd Bertoch
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84101
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Todd Bertoch

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CPL-01 in the Management of Postoperative Pain After Bunionectomy

We'll reach out to this number within 24 hrs